SiVEC Biotechnologies holds expertise and intellectual property (IP) for a platform technology that can be applied to target a wide range of diseases in humans and animals. Efforts are focused on broadening our bacterial platform’s applications, with an emphasis on ensuring strong IP protection.
BIOLOGICAL PLATFORM FOR NUCLEIC ACID DELIVERY
SiVEC is focused on developing a drug delivery platform that is characterized as non-pathogenic bacteria that constitutively generate therapeutic nucleic acids for targeted intracellular delivery to mucosal epithelial cells.
As proof-of-concept of the power of our platform technology, we are currently developing two therapeutic assets, a human influenza antiviral and an avian influenza antiviral.
SiVEC-IAV™ - BIOLOGICAL ANTIVIRAL FOR HUMAN FLU
SiVEC Biotechnologies is developing a biological antiviral technology, SiVEC-IAV™, for prevention and treatment of influenza, including viruses resistant to FDA-approved antiviral drugs.
SiVEC-AIV™ - BIOLOGICAL ANTIVIRAL FOR AVIAN FLU
SiVEC Biotechnologies is developing SiVEC-AIV™ as an innovative solution to treat and prevent the world’s most devastating poultry disease, avian flu.